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Available online 14 April 2017Interleukin (IL)-17 is crucial to osteoclast differentiation and activation. Osteocytes support osteoclast formation
and are thought to orchestrate bone remodeling in response to ﬂuid ﬂow. The contribution of IL-17 to osteocyte-
related bone resorption remains unclear. Here,we used the osteocyte-likeMLO-Y4 cell line to examine the role of
IL-17 and ﬂuid ﬂow in osteoclastogenesis. It was the ﬁrst time to demonstrate that IL-17A promotedMLO-Y4 cell
proliferation, enhanced expression of receptor activator of nuclear factor κ-B ligand (RANKL) and tumor necrosis
factor-α (TNF-α), and induced osteoclastogenesis when MLO-Y4 cells were co-cultured with bone marrow-de-
rived macrophage (BMM) cells. Additionally, shear stress upregulated osteoprotegerin expression in osteocytes,
downregulated the effect of IL-17A on RANKL and TNF-α expression, and attenuated IL-17A-activated osteoclas-
tic differentiation in the co-culture system of MLO-Y4 and BMM cells. Furthermore, we explored the signaling
pathways that potentially mediate these effects in osteocytes, and found that the extracellular signal-regulated
kinase (ERK)1/2 and signal transducer and activator of transcription (STAT3) pathways were suppressed by IL-
17A but induced by ﬂuid ﬂow. EphA2 signaling enhances osteoclastogenesis in osteocytes, and the intercellular
reversed EphA2-ephrinA2 signaling from osteocytes to BMM play an important role in IL-17A-dependent osteo-
clastic differentiation. EphB4 signaling inhibits osteoclastogenesis in osteocytes, and the intercellular reversed
EphB4-ephrinB2 signaling from osteocytes to BMM could inhibit IL-17A-dependent osteoclastic differentiation.
The current ﬁndings suggest that IL-17A as a promoter of bone resorption and ﬂuid shear stress critically regulate
bone remodeling via osteocyte-speciﬁc signaling pathways. IL-17 modulation-based approaches may be devel-
oped as a novel therapeutic strategy for enhancing bone remodeling efﬁciency and stability.erin; RAN
α; BMM, b
; STAT3, s
. This is a©2017TheAuthors. Publishedby Elsevier Inc. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Bone remodeling1. Introduction
Bone remodeling requires coupling between osteoclastic and osteo-
blastic activities and involves a dynamic balance between bone resorp-
tion and bone formation [1]. Osteocytes are believed to be responsible
for detecting and responding to mechanical loading and initiating
bone adaptation, and have been shown to support osteoclast formation
and activationwhen co-culturedwith osteoclast precursors [2,3]. When
subjected to ﬂuid ﬂow, osteocytes stimulate differentiation of osteo-
blasts via soluble factors [4].
Mechanical compressive force has been found to induce osteoblast-
like cells to overexpress IL-17 [5]. IL-17 is a cytokine family thatKL, receptor activator
onemarrow-derived
ignal transducer and
n open access article undercomprises six members, IL-17A to IL-17F, which are secreted primarily
by T helper 17 cells and are known to orchestrate osteoclast differenti-
ation and activation [6,7]. Like other pro-inﬂammatory cytokines, IL-
17 induces osteoclastogenesis via activation of the receptor activator
of nuclear factor κ-B ligand (RANKL)–receptor activator of nuclear fac-
tor κ-B (RANK)–osteoprotegerin (OPG) system [8]. IL-17 recruits im-
mune cells that express various cytokines and large amounts of
RANKL [8], and also affects osteoclastic resorption indirectly by inducing
osteoblasts to express IL-1, TNF-α and RANKL [6,7,9]. Blocking IL-17A
with neutralizing antibodies impairs osteoclast formation in bone mar-
row cell/osteoblast co-culture [10].
Recently, bidirectional ephrin-Eph signaling was reported to control
bone homeostasis [11]. EphrinA2-EphA2 signaling activation in osteo-
blastswas shown to inhibit osteoblast-speciﬁc genes (alkaline phospha-
tase, runt-related transcription factor 2, and Osterix), leading to bone
resorption [12]. EphrinB2-EphB4 signaling is markedly activated at
later stages of osteoclast differentiation, which inhibits osteoclast for-
mation [11]. Additionally, mitogen-activated protein kinase kinasethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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been suggested as downstream targets of the reactive oxygen species
formed upon IL-17 stimulation [13]. Furthermore, the signal transducer
and activator of transcription (STAT3) signaling pathway is essential for
T helper 17 cell differentiation [14,15], and is required for IL-23-mediat-
ed IL-17 production in a spontaneous arthritis animal model [16]. How-
ever, pathways involved in osteocyte-speciﬁc regulation of bone
resorption remain unclear. We hypothesize that ephrin-Eph, ERK1/2,
and STAT3 signaling are involved inmediating the effects of mechanical
stimulation in IL-17A-induced osteoclastogenesis.
To date, the role of IL-17 in bone remodeling has not been well ex-
plored. Here, we use ﬂuid shear stress on osteocytes to simulate bone
remodeling, and investigate the mechanisms of IL-17 regulation of
bone resorption via osteocyte-speciﬁc signaling pathways. Our ﬁndings
could help to elucidate the speciﬁc mechanisms that mediate load bear-
ing-related bone resorption, and facilitate understanding of orthodontic
tooth movement.
2. Materials and methods
2.1. Cell culture
MLO-Y4, kindly provided by Dr. Lynda Bonewald (University of Mis-
souri-Kansas City, Kansas City, MO, USA), is an immortalized cell line
with properties very similar to those of primary osteocytes in terms of
morphology and expression of several important molecular osteocyte
markers [17]. Cells were cultured on collagen-coated plates in α-mini-
mum essential medium (α-MEM) (GIBCO, Grand Island, NY, USA) con-
taining 5% fetal bovine serum (FBS) (BioWhittaker, Walkersville, MD,
USA), 5% bovine calf serum (HyClone, Logan, UT, USA) and 1% penicillin
and streptomycin under 5% CO2 at 37 °C [18].
2.2. Shear stress loading
Dynamic ﬂuid ﬂow is a mechanical stimulus that osteocytes experi-
ence in vivo with habitual loading [19]. MLO-Y4 cells were seeded on
type I rat tail collagen (BD Biosciences, Bedford, MA, USA)-coated glass
slides (75 mm × 38 mm × 1 mm) at 200,000 cells/slide and cultured
for 48 h to ensure 80%–90% conﬂuence at the time of the ﬂow experi-
ment. Peristaltic ﬂuid ﬂow (PFF) was generated by a Streamer® Shear
Stress Device (Flexcell, Hillsborough, NC, USA). Two-hour exposure to
peristaltic ﬂuid ﬂow (0.7± 0.3 Pa, 5 Hz) was selected as themechanical
stimulus to give maximal impact on the RANKL/OPG ratio [20]. A two-
speed pattern, 4 and 16 dyn/cm2, was used to represent low and high
PFF levels, respectively [21]. Six slides were placed in the ﬂow chamber,
which was placed in a CO2 incubator for the duration of the force-load-
ing experiment. The control samples were not exposed to ﬂow.
2.3. Exogenous IL-17A induction and IL-17RA blocking
For exogenous treatment withmouse IL-17A (R&D Systems, Minne-
apolis,MN, USA),MLO-Y4 osteocyteswere seeded at 10,000 cells/cm2 in
six-well plates and stimulated by IL-17A (0.5, 5, or 50 ng/mL) inα-MEM
containing 2.5% FBS and 2.5% BS for up to 72 h. For the blocking assay,
serum-starved MLO-Y4 cells were treated in the presence of 0.8 μg/mL
IL-17A receptor neutralizing antibody (R&D Systems) for 1 h, followed
by the stimulation of exogenous 50 ng/mL IL-17A. The control group
was cultured in normal medium under the same conditions.
2.4. EphA2 gene silencing and EphB4 Fc chimera protein induction
MLO-Y4 cells were seeded to be 80% conﬂuent at transfection. Lipo-
fectamine® RNAiMAX Reagent and Silencer® pre-designed siRNA for
mouse siEpha2 (#AM16708) or Silencer® Negative Control No. 1
siRNA (#AM4636) were diluted respectively in Opti-MEM® Medium
and then incubated together for 5 min according to manufacturer'sinstructions. Cells were incubated with siRNA-lipid complex for 24 h.
The ﬁnal siRNA concentration was 100 nM. All transfection reagents
and siRNAs were obtained from Thermo Fisher Scientiﬁc (Waltham,
MA, USA). Gene knockdown was validated by western blotting.
Serum-starved MLO-Y4 cells were treated 4 μg/mL of mouse-Fc or
mouse EphB4-Fc (R&D Systems) for 3 h at 37 °C as indicated. EphB4 sig-
naling was examined by western blotting.
2.5. Magnetic cell separation from co-culture system
A co-culture of MLO-Y4 cells andmouse bonemarrow-derivedmac-
rophages (BMMs) was carried out to explore the role of osteocytes in
osteoclastogenesis regulation. BMMs were a gift from Dr. Chen Ling (Li
Ka Shing Faculty of Medicine, HKU). The primary BMMculturewas con-
ducted as previously described [22]. Cells were collected by using tryp-
sin from co-culture for 3 days and re-suspended in buffer to be a single-
cell suspension.
Inmice, the CD11b antigen is expressed onmonocytes/macrophages
from bonemarrow [23]. CD11b+ cells (BMM) were separated from cell
suspension using CD11b MicroBeads, an LS Column, and a MiniMACS™
Separator according to themanufacturer's instructions (Miltenyi Biotec,
Teterow, Germany). Unlabeled cells (MLO-Y4) were also collect in the
ﬂow-through buffer. Collected cells were immediately re-suspended
in RNAlater® Stabilization Solution (Thermo Fisher).
2.6. Cell proliferation and apoptosis analysis
Cells were seeded in 96-well plates at 5000 cells/well. Assays were
conducted six times for each experiment. Cells were stimulated with
IL-17 (0.5, 5 or 50 ng/mL) for up to 72 h. Cell Counting Kit-8 (CCK-8;
10 μL per 100-μL reaction system; Sigma-Aldrich, St. Louis, MO, USA)
was added to each well and the cells were incubated for 1.5 h in 5%
CO2 at 37 °C. Cell proliferation was monitored by determining absor-
bance at 450 nm, with 650 nm used for wavelength correction, using
a SpectraMax M2 microplate reader (Molecular Devices, Orleans Drive
Sunnyvale, CA, USA). Measurements were recorded at 0, 24, 48 and
72 h after IL-17A treatment.
Annexin V-FITC and PI staining were conducted according to the
manufacturer's instructions. MLO-Y4 cells were seeded on six-well
plates (100,000 cells/well). Cells were pretreated with fresh medium
with or without IL-17A on the next day. Cells were then harvested
with 0.05% trypsin at 24, 48 and 72 h after initiation of treatment, and
stained with annexin V-FITC and PI according to the manufacturer's in-
structions (Thermo Fisher Scientiﬁc). The cells were analyzed immedi-
ately after staining using a FACSVerse ﬂow cytometer (Becton
Dickinson, San Jose, CA, USA) and FlowJo 10.2 software (Ashland, Ore-
gon, USA). Assays were conducted three times for each experiment.
2.7. Real-time quantitative PCR (qPCR)
The total RNA isolated from each sample was reverse transcribed
using SuperScript™ VILO Master Mix (Thermo Fisher Scientiﬁc) in a
Veriti Thermal Cycler (Applied Biosystems, Foster City, CA, USA). PCR
ampliﬁcation was performed using a StepOnePlus™ Real-Time PCR
System (Applied Biosystems). The copy numbers for the target
genes was normalized to the copy numbers for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). Expression of IL-17, IL-17R,
OPG/RANKL and TNF-αmRNA was evaluated. The primer sequences
are shown in Table 1.
2.8. Ephrin–Eph immunoﬂuorescence imaging
PFF-treated MLO-Y4 cells on glass slides were ﬁxed in 4% parafor-
maldehyde in PBS and blocked with goat serum. Two groups of cells
(A and B) were then incubated with primary antibodies (group A:
rabbit anti-ephrinA2 (1:200; Santa Cruz), mouse anti-EphA2
Table 1
Primers used in real-time polymerase chain reaction gene expression analysis.
Gene Primer sequences (5′-3′)
GAPDH
Forward GCATCTCCCTCACAATTTCCA
Reverse TGCAGCGAACTTTATTGATGGT
IL-17A
Forward ACCGCAATGAAGACCCTGAT
Reverse ATGTGGTGGTCCAGTTTCC
IL-17AR
Forward TCAGGGCCAGTGTGAAAACA
Reverse CATGTCGGGTTATCAGGGAAA
RANKL
Forward TGGGCCAAGATCTCTAACATGA
Reverse CATGATGCCGAAAGCAAATG
OPG
Forward CGAGAAAGACCTGCAAATCGA
Reverse GCATACATCAGGCCCTTCAAG
TNF-α
Forward ATGAGCACAGAAAGCATGATC
Reverse TACAGGCTTGTCACTCGAATT
EphrinA2
Forward GCCACAGGGATGAGGTGAA
Reverse GGACCAAATAACAGGACACAGA
EphrinB2
Forward TCGGTTGGCTACGTTTTGGT
Reverse ACGCACAGGACACTTCTCAATG
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and rat anti-EphB4 (1:100; Abcam)) and ﬁxed at 4 °C in a humidiﬁed
box overnight. Group A cells were then incubated with Alexa Fluor
488 goat anti-rabbit IgG (1:500; Abcam) and Alexa Fluor 647 goat
anti-Mouse IgG (1:500; Abcam), and group B cells were incubated
with Alexa Fluor 488 goat anti-rabbit IgG (1:500; Abcam) and
Alexa Fluor 647 goat anti-rat IgG (1:500; Abcam) at 37 °C in a humid-
iﬁed box for 2 h. All cells were then stained in DAPI for 10 min. Im-
ages were acquired using a Carl Zeiss LSM 780 ﬂuorescence
microscope (Jena, Germany) and ﬁve visual ﬁelds on each slide
were randomly selected. The images were processed using Zen 2
core Software (Carl Zeiss).2.9. Western blotting
Cell lysates was prepared using RIPA cell-lysis buffer (Thermo Fisher
Scientiﬁc). Total protein concentration was determined using the BCA
reagent system (Thermo Fisher Scientiﬁc). Protein extracts (20 μg of
total cell proteins) were subjected to 7.5% to 15% SDS-PAGE and
electrotransferred onto polyvinylidene diﬂuoride membrane. Nonspe-
ciﬁc binding was blocked using Tris-buffered saline with 0.5% Tween
20 containing 5% skimmed milk powder. Speciﬁc antigens were
immunodetected using appropriate primary and secondary antibodies
and visualized using enhanced chemiluminescence detection reagents
(ECL Plus; GE Healthcare, London, UK). The membranes were stripped
using Restore Western Blot Stripping Buffer (Thermo Fisher Scientiﬁc)
and reprobed for β-actin or GAPDH to conﬁrm that equivalent amounts
of proteins had been loaded and transferred. The primary antibodies
were: rabbit anti-RANKL (1:500, Santa Cruz), rabbit anti-ERK1/2
(1:1000, Cell Signaling Technology), rabbit anti-pERK1/2 (1:1000, Cell
Signaling Technology), rabbit anti-STAT3 (1:1000, Cell Signaling Tech-
nology), rabbit anti-pSTAT3 (1:1000, Cell Signaling Technology), rabbit
anti-STAT3 (1:1000, Cell Signaling Technology), rabbit anti-ephrinA2
(1:1000; Santa Cruz), mouse anti-EphA2 (1:1000; Santa Cruz), rabbit
anti-ephrinB2 (1:1000; Abcam), rat anti-EphB4 (1:1500; Abcam), rab-
bit anti-GAPDH (1:1000, Cell Signaling Technology), and rabbit anti-β-
actin (1:1000, Cell Signaling Technology). Secondary antibodies were
all obtained from Cell Signaling Technology (1:3000).2.10. Enzyme-linked immunosorbent assay (ELISA)
PFF-treated cells were cultured in 4-well dishes in fresh medium for
another 24 hwith orwithout IL-17A. Themediawere collected and cen-
trifuged to removal cell debris. IL-17A, OPG, sRANKL and TNF-α levels in
the culture supernatants were measured by ELISA (all kits from R&D
Systems) according to the manufacturer's instructions. The optical den-
sity of each well was determined using a SpectraMax M2 microplate
reader at to determine absorbance at 450 nm, with 540 nm used for
wavelength correction.
2.11. TRAP staining of co-culture system for Osteoclastogenesis
MLO-Y4 cells were seeded at 500 cells/cm2 in collagen-coated 12-
well plates (day 0). BMMs were added at 2500 cells/cm2 at day 2 and
then co-cultured in DMEM containing 5% FBS with or without
50 ng/mL IL-17 for 7 days. Media were changed every 2 days. On day
7 after BMM plating, cells were ﬁxed and stained for tartrate-resistant
acid phosphatase (TRAP) using a leukocyte acid phosphatase kit
(Sigma-Aldrich). Cells were imaged using a light microscope with a
20× objective, and counted by 2 blinded investigators. TRAP+ cells
were counted and classiﬁed as mononuclear, multinuclear (2–10 nu-
clei), or giant cells (≥10 nuclei), as described previously [24,25].
The effect of soluble factors released by osteocytes on osteoclas-
togenesis was studied using conditioned media from MLO-Y4 cells.
After ﬂow exposure, cell on glass slides were transferred to 4-well
sterile dishes (Thermo, Rochester, NY, USA) with 4 mL of fresh
media added. At 24 h after ﬂow exposure, conditioned media were
collected and added immediately to the BMM/MLO-Y4 co-culture
to replace 50% of the original culture media. Media from osteocytes
not treated with PFF were also collected. This process was repeated
every day until day 7.
We also used conditionedmedia for indirect co-culture. BMMswere
seeded at 2500 cells/cm2 in collagen-coated 12-well plates and cultured
in four kinds of conditioned media: medium from osteocytes, medium
from osteocytes treated with IL-17A, medium from osteocytes treated
with PFF, andmedium from osteocytes pretreated with PFF in the pres-
ence of IL-17A. Media were changed daily until day 7.
2.12. Statistical analysis
One way analysis of variance (ANOVA) was used to compare data
from more than two groups. Two signiﬁcance levels, p ≤ 0.05 (*) and p
≤ 0.01 (**), were used throughout the statistical analysis. The data are
reported as means ± SD. Each experiment was repeated at least three
times independently.
3. Results
3.1. IL-17A induced MLO-Y4 cell proliferation but did not affect apoptosis
IL-17A enhanced theproliferation ofMLO-Y4 after 48h incubation in
a concentration-dependent manner, with the greatest effect observed
for 50 ng/mL IL-17A (Supplementary Fig. 1A). However, the IL-17A in-
duction had no signiﬁcant effect on MLO-Y4 apoptosis (Supplementary
Fig. 1B).
3.2. Osteoclastogenic factor expression was downregulated by PFF but en-
hanced by IL-17A; while the effect of IL-17A was attenuated by PFF stimu-
lation in MLO-Y4 cells
To investigate the potential effect of PFF on bone remodeling in
MLO-Y4 cells, the expression of RANKL and OPG was investigated.
OPG mRNA expression and secretion was signiﬁcantly enhanced after
force application (Fig. 1A and B), whereas secreted RANKL (sRANKL)
levels decreased (Fig. 1B). The decrease in RANKL/OPG mRNA and the
Fig. 1.Peristalticﬂuidﬂow(PFF) and IL-17A regulated osteoclastogenesis by regulatingRANKL, OPG, and TNF-α inMLO-Y4 osteocytes. q-PCR (A) and ELISA (B) analysis of RANKL, OPG and
TNF-αmRNA expression and RANKL/OPG ratio in cells treated with low-PFF (L-PFF) and high-PFF (H-PFF) for 2 h. (C)Western blot analysis of membrane-bound RANKL expression after
shear stress. q-PCR (D) and ELISA (E) analysis of RANKL, OPG and TNF-αmRNA expression, and RANKL/OPG ratio in cells treated with 0.5, 5, or 50 ng/mL IL-17A, or 0.8 μg/mL IL-17RA
antibody + 50 ng/mL IL-17A. (F) Western blotting analysis of membrane-bound RANKL expression treated with IL-17A with or without anti-IL-17RA. q-PCR (G) and ELISA (H)
analysis of RANKL, OPG and TNF-αmRNA expression, and RANKL/OPG ratio in cells treated with 50 ng/mL IL-17A with or without L-PFF or H-PFF pretreatment. (I) Western blotting
analysis of membrane-bound RANKL expression treated with 50 ng/mL IL-17A with or without PFF pretreatment (bars represent means ± SD from 3 independent studies,*p b 0.05,
**p b 0.01).
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α, which promotes osteoclast differentiation directly or indirectly [26],
signiﬁcantly downregulated by PFF; this further conﬁrms that shear
stress can suppress osteoclastogenic differentiation. It was particularly
notable that high PFF had stronger effects on secretion of TNF-α than
low PFF (Fig. 1B).
The effect of IL-17A on bone remodeling factors in MLO-Y4 was also
investigated. Addition of IL-17A to MLO-Y4 cells increased in RANKLmRNA expression and sRANKL secretion, thereby leading to a marked
RANKL/OPG ratio increase. Enhanced TNF-α expression also indicated
the osteoclastogenic effect of IL-17A. Antibodies against the IL-17A re-
ceptor were used to block IL-17A. The effects of 50 ng/mL IL-17A on
RANKL/OPG ratio and TNF-αwere attenuated by anti-IL-17RA antibody
(0.8 μg/mL) (Fig. 1D, E).
We next investigated the effect of IL-17A on MLO-Y4 cells after
mechanical stimulation. PFF pretreatment signiﬁcantly attenuated
14 C. Liao et al. / Bone 101 (2017) 10–20the IL-17A-induced increase in RANKL/OPG mRNA ratio and
sRANKL/OPG ratio, and also attenuated the IL-17A-induced in-
crease in TNF-α mRNA and protein levels (Fig. 1G, H). No evidentFig. 2. Ephrin-Eph, STAT3 and ERK1/2 signaling were regulated in MLO-Y4 cells subjected to s
EphA2 (red) and ephrinB2 (green)-EphB4 (red) in osteocytes treated with L-PFF or H-PFF for
ephrinA2–EphA2, ephrinB2–EphB4, P-ERK1/2, ERK1/2, P-STAT3 and STAT3 treated with PFF f
mL IL-17RA antibody (D), or treated with 50 ng/mL IL-17A with or without 2 h PFF pretreatmechange was observed in membrane-bound RANKL expression
caused by either PFF or IL-17 or these two inductions together
(Fig. 1C, F, I).hear stress and IL-17A treatment. (A) Immunoﬂuorescence staining of ephrinA2 (green)-
2 h. Nuclei were stained with DAPI (blue). Bar = 50 μm. (B) Western blotting analysis of
or 2 h (B and C), or treated with 0.5, 5 or 50 ng/mL IL-17A, or 50 ng/mL IL-17A + 0.8 μg/
nt (E).
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17A, while PFF antagonized IL-17A regulation in MLO-Y4 cells
To investigate the retroactivemechanism of PFF simulation onMLO-
Y4 cells, ephrin-Eph, ERK1/2 and STAT3 signaling were analyzed.
Ephrin-Eph localization was conﬁrmed by immunoﬂuorescence imag-
ing, which indicated that ephrinA2-EphA2 and ephrinB2-EphB4 were
located on the membrane of MLO-Y4 cells, and could be expressed in
the nuclei after force loading (Fig. 2A). After PFF treatment, ephrinA2
and EphA2 expressionwas decreased, whereas ephrinB2 and EphB4 ex-
pression was increased (Fig. 2B). Additionally, PFF increased P-ERK1/2Fig. 3. Inhibited EphA2 signaling and enhanced EphB4 signaling attenuated IL-17-dependent ost
(B) qPCR analysis of RANKL, OPG and TNF-αmRNA expression and RANKL/OPG ratio in cells tre
ERK1/2 and P-STAT3 treated with siControl or siEphA2with or without IL-17A. (D)Western blo
and TNF-αmRNA expression and RANKL/OPG ratio in cells treated with Control-Fc or EphB4-F
with Control-Fc or EphB4-Fc with or without IL-17A.and P-STAT3 but not ERK1/2 and STAT3, indicating that PFF activated
the two pathways by facilitating ERK1/2 and STAT3 phosphorylation
(Fig. 2C).
Furthermore, ephrinA2-EphA2 signalingwas activated by increasing
exogenous IL-17A (0.5, 5 or 50 ng/mL), while IL-17A suppressed
ephrinB2-EphB4 signaling (Fig. 2D). Additionally, P-ERK1/2 and P-
STAT3 levels were decreased with increasing IL-17A. In the blocking
assay, anti-IL-17RA antibody counteracted the effects of IL-17A on
ephrinA2-EphA2, ephrinB2-EphB4 and P-ERK1/2 and P-STAT3 levels.
The IL-17A-dependent activation of ephrinA2-EphA2 signaling
was attenuated by PFF pretreatment, whereas the IL-17A-mediatedeoclastogenesis. (A)Western blotting analysis of EphA2 after siEphA2 transfection for 24 h.
atedwith siControl or siEphA2with or without IL-17A. (C)Western blotting analysis of P-
tting analysis of EphB4 after EphB4-Fc treatment for 3 h. (E) qPCR analysis of RANKL, OPG
c with or without IL-17A. (F) Western blotting analysis of P-ERK1/2 and P-STAT3 treated
16 C. Liao et al. / Bone 101 (2017) 10–20reduction in ephrinB2-EphB4 signaling was enhanced by PFF pre-
treatment (Fig. 2E). Similarly, the IL-17A-dependent inhibition of
P-ERK1/2 and P-STAT3 was reversed by 2-hour PFF stimulation
(Fig. 2E).
3.4. Intracellular EphA2 and EphB4 signaling regulated IL-17-dependent os-
teoclastogenesis in osteocytes
The effect of EphA2 knockdown in MLO-Y4 cells by siRNA was con-
ﬁrmed by western blotting analysis (Fig. 3A). The knockdown of
EphA2 signiﬁcantly decreased IL-17-stimulated RANKL and TNF-α,
thereby leading to the decreasing of RANKL/OPG ratio (Fig. 3B), indicat-
ing that EphA2 signaling plays an important role in IL-17 downstream
pathway. We further investigated whether EphA2 signaling mediatedFig. 4.Osteoclastic differentiation in direct co-culture ofMLO-Y4 cells and BMMs for 7 days. No T
with IL-17 (A-c). BMM andMLO-Y4 cell co-culture in normalα-MEMmedium (A-d), or treated
MLO-Y4 cells pretreated with H-PFF (A-f). Bar= 100 μm. Percentage values for mononuclear, mIL-17 pathway via STAT3 or ERK1/2 (Fig. 3C). The reduced expression
of P-STAT3 and P-ERK1/2 caused by IL-17 was reversed by siEphA2,
however, the knockdown of EphA2 had no direct effect on STAT3 and
ERK1/2 signaling (Fig. 3C).
EphB4-Fc was used to enhance EphB4 signaling in osteocytes (Fig.
3D). The enhanced EphB4 signaling signiﬁcantly down-regulated IL-
17-sitmulated RANKL and TNF-α and up-regulated IL-17-inhibited
OPG expression, thereby, leading to the decrease of RANKL/OPG ratio
(Fig. 3E). The above results indicated that EphB4 signalingwas involved
in osteoclastogenic pathway of IL-17.We further investigated the role of
EphB4-Fc on STAT3 and ERK1/2 signaling, which showed that EphB4-Fc
could enhance P-STAT3 and P-ERK1/2 notably and further attenuated
the effect of IL-17 (Fig. 3F). Hence, EphB4 signaling could inhibit
osteoclastogenic pathway of IL-17 via STAT3 or ERK1/2.RAP+ cells were observed in BMM-only (A-a) orMLO-Y4-only (A-b) or BMM-only treated
with 50 ng/mL IL-17A(A-e), or treatedwith 50 ng/mL IL-17A in conditionedmedium from
ultinuclear and giant TRAP+ cells were derived from three independent experiments (B).
17C. Liao et al. / Bone 101 (2017) 10–203.5. IL-17A promoted osteoclastogenesis in a MLO-Y4 and BMM co-culture
system, which was attenuated by PFF
To verify the function of IL-17A in osteoclastogenesis, we co-cul-
tured MLO-Y4 osteocytes with BMM osteoclast precursors. Comparing
with BMM or MLO-Y4 cell culture (Fig. 4A-a and b), TRAP staining
showed that the osteocytes facilitated osteoclast formation in the co-
culture system in the absence of exogenous RANKL (Fig. 4A-d). IL-17A
signiﬁcantly promoted multinuclear and giant TRAP+ cells (Fig. 4A-e)
in co-culture rather than in single BMM cells (Fig. 4A-c). Additionally,
conditioned medium from 2-hour ﬂow exposure appeared to diminish
the osteoclastic effect of IL-17A, with fewer multinuclear and giant
TRAP+ cells formed in the co-culture system (Fig. 4A-e). Percentage
values for TRAP+ mononuclear, multinuclear and giant cells were de-
rived (Fig. 4B).
Indirect co-culture was performed to explore the effect of soluble
factors secreted by osteocytes on osteoclastic differentiation in theFig. 5. Intercellular reversed Eph-Ephrin signalingmediated osteoclastogenesis. (A) qPCR analys
OPG and TNF-α inMLO-Y4 after cell separation from co-culture with or without IL-17 induction
culture with or without IL-17 induction. (D) qPCR analysis of RANK in separated BMM after co-
RANK, ephrinA2 (green)-EphA2 (red) and ephrinB2 (green)-EphB4 (red) in BMM. Bar = 50
siEphA2 or EphB4 pretreated osteocytes. (G) TRAP staining of co-culture of BMM with siEphA2absence of direct cell–cell contact with osteoclast precursors. However,
no TRAP+multinuclear cells were observed when BMMs were exposed
to fresh MLO-Y4 conditioned medium for 7 days (Supplementary Fig.
2B-b). Additionally, IL-17A did not induce formation of a TRAP+ cell
population in this indirect co-culture system (Supplementary Fig. 2B-
c). Conditioned medium from PFF-pretreated MLO-Y4 cells had no ap-
parent effects on differentiation of BMMs in either the presence or ab-
sence of IL-17A (Supplementary Fig. 2B-d and e). This indicates that
the soluble factors secreted by MLO-Y4 cells were not sufﬁcient to in-
duce BMMs to differentiate into TRAP+ cell, even with IL-17A
stimulation.
3.6. Intercellular EphA2-ephrinA2 and EphB4-ephrinB2 signaling between
osteocytes and BMM mediated osteoclastogenesis
The differences of expression of osteoclastogenic factors between
osteocytes and BMM showed that RANKL and OPG were moreis of RANK, RANKL, OPG and TNF-α inMLO-Y4 and BMMcells. (B) qPCR analysis of RANKL,
. (C) qPCR analysis of RANK, RANKL, OPG and TNF-α in BMM after cell separation from co-
culture with siEphA2 or EphB4 pretreated osteocytes. (E) Immunoﬂuorescence staining of
μm. (F) qPCR analysis of ephrinA2 and ephrinB2 in separated BMM after co-culture with
or EphB4 pre-treated osteocytes for 7 days with IL-17 induction.
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expressed in BMM (Fig. 5A). After 72 h-co-culture, CD11b+ BMM was
selected from co-culture cells by magnetic cell separation and changes
in expression of these osteoclastogenic factorswere analyzed aftermag-
netic cell separation (Fig. 5B and C). Attractively, RANKL in osteocytes
signiﬁcantly up-regulated after co-culture and even higher with IL-17
induction (Fig. 5B); while similar pattern could be found in RANK in
BMM from co-culture, even more apparently (Fig. 5C).
Based on the importance of RANKL–RANK–OPG system in bone re-
modeling, we further focused on RANK in BMM and veriﬁed the inter-
cellular effects of EphA2 and EphB4 signaling from osteocyte. It was
shown that the inhibited EphA2 and enhanced EphB4 signaling could
signiﬁcantly decrease RANK expression after co-culture (Fig. 5D). Local-
ization of RANK, EphrinA2, EphA2, EphrinB2 and EphB4 on BMM was
conﬁrmed by immunoﬂuorescence imaging (Fig. 5E). EphrinA2 mRNA
expression signiﬁcantly increased after co-culture and could be
counteracted by inhibiting EphA2 signaling from osteocytes, and simi-
larly, enhanced EphB4 signaling in osteocytes could reverse the reduc-
tion of ephrinB2 expression caused by co-culture (Fig. 5F). Lastly, we
veriﬁed the role of reversed Eph-ephrin signaling in IL-17 induced co-
culture. EphA2-knockdown osteocytes and EphB4-Fc-osteocytes could
not assist the osteoclastic differentiation of BMM even with IL-17 stim-
ulation (Fig. 5G). Hence, intercellular reversed EphA2-ephrinA2 and
EphB4-eprinB2 signaling could play an important role in osteoclastic
differentiation.
4. Discussion
In this study, we demonstrated that exogenous IL-17A accelerated
osteocyte proliferation after 48 h, with no signiﬁcant effects on cell ap-
optosis until 72 h, consistent with previous studies on IL-17-induced
proliferation in various cells with different origins [13,27,28]. Further-
more, exogenous IL-17A increased TRAP+multinuclear cells in a co-cul-
ture system of MLO-Y4 osteocytes and BMM osteoclast precursors, but
could not induce osteoclastic differentiation of BMMs in the absence
of osteocytes (Fig. 4A), indicating that IL-17A may orchestrate bone re-
sorption via osteocyte-speciﬁc signaling pathways.
IL-17 plays roles in bone erosion via activation of RANKL–RANK–
OPG system [29]. RANKL exists in two forms:membrane-bound and se-
creted ones, both of which regulate osteoclastogenesis [30]. IL-17 has
been shown to induce macrophage colony-stimulating factor (M-CSF)
and RANKL expression in human mesenchymal stem cells, thereby
supporting osteoclastogenesis, both in vitro and in vivo [13]. In our
study, IL-17A-induced enhancement of RANKL mRNA and sRANKL
levels and increased RANKL/OPG ratio (Fig. 2D, E), indicating osteoclas-
tic differentiation.
Oscillatory ﬂuid ﬂow has an anti-osteoclastogenic effect on the
RANKL/OPG signaling axis in osteocytes, and decreases the osteoclasto-
genesis-supporting potential of MLO-Y4 cells co-cultured with
RAW264.7 pre-osteoclasts [3]. Osteocytes subjected to PFF also stimu-
late osteoblasts differentiation in vitro via soluble factors [4]. Consis-
tently, we found that OPG was upregulated by PFF, which led to
decreased RANKL/OPG ratio, indicating inhibition of osteoclastogenesis.
Importantly, we demonstrated that the osteoclastogenic activity of IL-
17A was attenuated by PFF-conditioned medium (Fig. 4A-e). This may
result from the increased OPG caused by PFF, as binding of OPG to
RANKL not only blocks osteoclastogenesis, but also decreases survival
of pre-existing osteoclasts [30].
Osteoclast formation in vivo is thought to be induced by direct cell–
cell contact of pre-osteoblastic/stromal cells with monocyte/macro-
phage osteoclast precursors [30,31].We found that TRAP+multinuclear
cells were formed in vitro in direct co-culture of BMMs with MLO-Y4
(Fig. 4A), mainly due to membrane-bound RANKL of MLO-Y4, which
constitutes the major physiological regulator of osteoclastogenesis [32,
33]. Moreover, the formation of TRAP+ multinuclear cells in indirect
co-culture could not induced by sRANKL. sRANKL was secreted fromosteocytes under physiological conditions, and could be downregulated
by mechanical stimulation, or increased by exogenous IL-17A. Hence,
the soluble factors released by IL-17A- andmechanically-stimulated os-
teocytes were not the major regulators of osteoclastogenesis, but they
were able to regulate osteoclastic differentiation when accompanied
by other supporting cells including bonemarrowmacrophages. Howev-
er, it was previously demonstrated that IL-17 induced osteoclastogene-
sis in cultures of human CD11b-positive cells in the absence of
osteoblasts or exogenous RANKL [34]. This discrepancy could result
from the fact that IL-17 upregulates RANK expression in osteoclast pre-
cursors to sensitize them to RANKL [7], but the effectiveness of this pro-
cess may differ in different precursor cells.
The mechanism of IL-17 stimulation of bone resorption via osteo-
cyte-speciﬁc pathways in the presence and absence of shear stress re-
mains unclear. Previous studies indicated that EphA2 can be up-
regulated by IL-17A in keratinocytes [35]. Here, we demonstrated that
IL-17A activated ephrinA2-EphA2 signaling, leading to osteoclastic dif-
ferentiation. Mechanical compressive force has been shown to upregu-
late ephrinA2 and EphA2 expression in periodontal ligament ﬁbroblasts
[36]. In our study, when osteocytes were exposed to PFF, ephrinA2 and
EphA2 expression was downregulated, leading to osteoblastic differen-
tiation, which weakened the osteoclastic effect of IL-17A. When EphA2
signaling was silenced by siRNA, IL-17-dependent RANKL in osteocytes
and RANK in BMM selected from co-culture were decreased (Figs. 3D
and 5B), which revealed the osteoclastogenic role of EphA2 signaling
in osteocytes and from osteocytes to BMM. The down-regulation of
ephrinA2 expression in BMMfurtherly veriﬁed the existence of intercel-
lular reversed EphA2-ephrinA2 signaling. This is the ﬁrst time that
EphA2-ephrinA2 signaling has been reported to regulate osteocytes
and BMMs in osteoclastogenesis.
Mechanical strain upregulates ephrinB2 in periodontal ligament ﬁ-
broblasts, contributing to osteogenesis at sites of tension in orthodontic
tooth movement [37]. Consistently, we identiﬁed that IL-17A sup-
pressed ephrinB2-EphB4 signaling, which was weakened by shear
stress. Enhancing EphB4 signaling in osteocytes decreased IL-17-depen-
dent RANKL and TNF-α expression and activated STAT3 and ERK 1/2
signaling (Fig. 3E and F), and the intercellular reverse signaling from
EphB4 to ephrinB2 led to the reduction of RANK in BMM,whichmay ex-
plain the inhibition of osteoclastic differentiation in the co-culture sys-
tem (Fig. 5F).
In our study, IL-17A decreases the contents of P-ERK1/2, which has
been suggested as the downstream target for IL-17A. An in vivo model
of tooth movement previously indicated enhanced P-ERK1/2 contents
under tension [38]. In vitro,ﬂuid shear stress has been shown to activate
ERK1/2 in human umbilical vein endothelial cells [39]. Similarly, we
found thatﬂuidﬂow stimulated P-ERK1/2production.Hence, themech-
anism for promotion or inhibition of bone resorption could involve IL-
17A-mediated inhibition or ﬂow-mediated activation of ERK1/2 in
osteocytes.
Loss-of-function mutation of STAT3 in osteoblasts and osteocytes
has been shown to diminish load-driven bone formation [40]. We
found that the phosphorylation of STAT3 (P-STAT3) was inhibited by
IL-17A and activated by PFF in osteocytes, indicating STAT3 involvement
in the signaling pathway downstream of IL-17A and shear stress stimu-
lation. However, it has been demonstrated that STAT3 activation in os-
teoblasts is required for RANKL induction and osteoclastogenesis [41].
It is possible that there is some crosstalk between osteoblasts and
osteocytes. Hence, ephrin-Eph, ERK1/2 and STAT3 signaling are in-
volved in the effect of IL-17A on osteoclastogenesis under mechanical
stimulation.
Croes et al. recently has reported that IL-17A and IL-17F similarly ex-
hibited strong osteogenic effects when exposed directly to humanmes-
enchymal stem cell [42]. In future, the role of IL-17A in osteoblastic
differentiation and forward ephrin-Eph signaling need to be investigat-
ed and in vivo orthodontic models should be used to verify our ﬁndings
regarding IL-17A-mediated bone remodeling.
Fig. 6. Scheme of the ﬁndings of this study. IL-17A induced osteoclastic differentiation by activating the RANKL/OPG system and TNF-α in osteocytes in the presence of direct cell–cell
contact with osteoclast precursors. During osteoclastogenesis, suppression of the ERK1/2 and STAT3 pathways in osteocytes and activation of reversed Eph-ephrin signaling between
osteocytes and osteoclast precursors played roles downstream of IL-17A. Fluid ﬂow through canaliculi surrounding the osteocytes stimulated biochemical responses, resulting in
inhibition of osteoclastogenesis mainly due to increased OPG. ERK1/2 and STAT3 pathway activity was enhanced and ephrin-Eph signaling was regulated by ﬂuid ﬂow, which may
ultimately attenuate the osteoclastic effect of IL-17A.
19C. Liao et al. / Bone 101 (2017) 10–20In summary (Fig. 6), we have demonstrated that IL-17A, a potential
inducer of osteoclastic differentiation, enhanced TRAP+ multinuclear
cells formation induced by cell–cell contact between osteocytes and os-
teoclast precursors; PFF suppressed osteoclastic differentiation and de-
creased TRAP+ multinuclear cells formation via soluble factors
secreted by osteocytes; importantly, the effect of IL-17A on osteoclasto-
genesis was reduced by peristaltic ﬂuid ﬂow; furthermore, the ephrin-
Eph, ERK1/2 and STAT3 pathways may be involve in signaling from os-
teocytes to osteoclast precursors, which represents the beginning of the
remodeling cycle. This ﬁnding represents a novel osteocyte regulation
mechanism and offers unique insight into the regulation of bone remod-
eling during orthodontic tooth movement. Interventions of IL-17 may
contribute to novel therapeutic strategies for bone remodeling with in-
creased treatment efﬁciency and stability.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bone.2017.04.003.
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